CYSTARAN- cysteamine hydrochloride solution
Leadiant Biosciences, Inc.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use CYSTARAN
®safely and effectively. See full prescribing information for CYSTARAN.
CYSTARAN (cysteamine ophthalmic solution) 0.44%, for topical ophthalmic use Initial U.S. Approval: 1994 INDICATIONS AND USAGECYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. ( 1) DOSAGE AND ADMINISTRATIONInstill one drop of CYSTARAN in each eye, every waking hour. ( 2) DOSAGE FORMS AND STRENGTHSOphthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%). ( 3) CONTRAINDICATIONSNone. ( 4) WARNINGS AND PRECAUTIONSTo minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use. ( 5.1) ADVERSE REACTIONSThe most common adverse reactions (incidence approximately 10% or greater) are sensitivity to light, redness, eye pain/irritation, headache and visual field defects. ( 6) To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at 1-888-393-4584 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION. Revised: 2/2022 |
CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
Instill one drop of CYSTARAN in each eye, every waking hour.
Do not touch dropper tip to any surface, as this may contaminate the solution.
Discard after 1 week of use.
Ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).
To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy.
There have also been reports associated with ophthalmic use of cysteamine; however, all of these patients were on concurrent oral cysteamine.
CYSTARAN contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration [see Patient Counseling Information (17)] .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described below reflect exposure in controlled clinical trials of six months to 19 years duration in approximately 300 patients.
The most frequently reported ocular adverse reactions occurring in ≥10% of patients were sensitivity to light, redness, and eye pain/irritation, headache and visual field defects.
Risk Summary
There are no adequate and well controlled studies of ophthalmic cysteamine in pregnant women to inform any drug associated risks. Oral administration of cysteamine to pregnant rats throughout the period of organogenesis was teratogenic at doses 86 to 345 times the recommended human ophthalmic dose (based on body surface area) [see Data] . CYSTARAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Data
Animal Data
Teratology studies have been performed in rats at oral doses in the range of 37.5 mg/kg/day to 150 mg/kg/day (86 to 345 times the recommended human ophthalmic dose based on a body surface area) and have revealed cysteamine bitartrate to be teratogenic. Observed teratogenic findings were intrauterine death, cleft palate, kyphosis, heart ventricular septal defects, microcephaly, exencephaly, and growth deficits.
Risk Summary
There is no information regarding the presence of cysteamine in human milk, the effects on the breastfed infants, or the effects on milk production. Cysteamine administered orally is present in milk of lactating rats. It is not known whether measurable levels of cysteamine would be present in maternal milk following topical ocular administration of CYSTARAN.
The safety and effectiveness of CYSTARAN (cysteamine ophthalmic solution) 0.44% have been established in pediatric patients.
When the clinical studies with CYSTARAN were conducted, the reduced life expectancy from cystinosis did not make it possible to include patients in the geriatric age range.
The effect of renal impairment on the pharmacokinetics of cysteamine following ophthalmic administration of cysteamine ophthalmic solution has not been evaluated because ophthalmic exposure compared to systemic exposure is negligible. The majority of the patients in the ophthalmic clinical studies are assumed to have had some degree of renal impairment due to their underlying systemic disease. The total daily ophthalmic dose is less than 2% of the recommended oral daily dose of cysteamine; thus, the systemic exposure following ophthalmic administration is expected to be negligible compared to oral administration.
CYSTARAN is a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride, equivalent to 4.4 mg/mL of cysteamine (0.44%) as the active ingredient. Cysteamine is a cystine-depleting agent which lowers the cystine content of cells in patients with cystinosis.
Molecular Formula: C
2H
7NS HCl
Molecular Weight: 113.61
Each milliliter of CYSTARAN contains: Active: cysteamine 4.4 mg (equivalent to cysteamine hydrochloride 6.5 mg); Preservative: benzalkonium chloride 0.1 mg; Inactive Ingredients: sodium chloride, hydrochloric acid and/or sodium hydroxide (to adjust pH to 4.1-4.5), and purified water.
Carcinogenesis
Cysteamine has not been tested for its carcinogenic potential in long-term animal studies.
Mutagenesis
Cysteamine was not mutagenic in the Ames test. It produced a negative response in an in vitrosister chromatid exchange assay in human lymphocytes but a positive response in a similar assay in hamster ovarian cells.
Impairment of Fertility
Repeat breeding reproduction studies were conducted in male and female rats. Cysteamine was found to have no effect on fertility and reproductive performance at an oral dose of 75 mg/kg/day (173 times the recommended human ophthalmic dose based on body surface area). At an oral dose of 375 mg/kg/day (864 times the recommended human ophthalmic dose based on body surface area), it reduced the fertility of the adult rats and the survival of their offspring.
Clinical efficacy was evaluated in controlled clinical trials in approximately 300 patients. The primary efficacy end point was the response rate of eyes that had a reduction of at least 1 unit in the photo-rated Corneal Cystine Crystal Score (CCCS) at some time point during the study when baseline CCCS ≥1, or a lack of an increase of more than 1 unit in CCCS throughout the study when baseline CCCS <1.
Study 1 combined the data from three smaller studies. For eyes with a lower baseline of CCCS <1, the response rate was 13% (4/30) [95% CI: (4, 32)]. For eyes with a higher baseline of CCCS ≥1, the response rate was 32% (94/291) [95% CI: (27, 38)].
Study 2 evaluated ocular cystinosis patients who had a baseline of CCCS ≥1. The response rate was 67% (10/15) [95% CI: (38, 88)].
Study 3 also evaluated ocular cystinosis patients; for eyes with a baseline of CCCS ≥1, the response rate was 33% (3/9) [95% CI: (8, 70)].
Corneal crystals accumulate if CYSTARAN is discontinued.
Fifteen (15) mL of CYSTARAN (cysteamine ophthalmic solution) 0.44% is supplied in the following bottles:
Storage: Store in freezer at -25°C to -15°C (-13°F to 5°F) in the original carton. Thaw for approximately 24 hours before use. Store thawed bottle at 2°C to 25°C (36°F to 77°F) for up to 1 week. The thawed bottle does not require refrigeration between use. Do not refreeze the thawed medication. Discard after 1 week of use.
Storage of Bottles
Risk of Contamination
Patients should be advised not to touch the eyelid or surrounding areas with the dropper tip of the bottle. The cap should remain on the bottle when not in use.
CYSTARAN (cysteamine ophthalmic solution) 0.44% is distributed by Leadiant Biosciences, Inc., Gaithersburg, MD 20878.
NDC 54482-020-02
cystaran ®
(cysteamine ophthalmic
solution) 0.44%
For Topical Ophthalmic Use
Sterile
15 mL
Rx only
Active Ingredient:Each mL
contains 6.5 mg cysteamine
hydrochloride, equivalent to 4.4 mg
cysteamine.
Inactive Ingredients:
Benzalkonium chloride
(preservative); Sodium chloride;
hydrochloric acid and/or sodium
hydroxide (to adjust pH) and
purified water.
Dosage:See Prescribing Information.
Store in freezer in original carton at -25°C
to -15°C (-13°F to 5°F). Thaw in original carton for approximately 24 hours
before use. Store thawed bottle at 2°C to
25°C (36°F to 77°F) for up to 1
week. Do not refreeze thawed medication.
Discard
after 1 week of use, even if there
is remaining drug product.
Avoid touching dropper tip to any
surface.
For Topical Ophthalmic Use
cysc-5-m
Distributed by:
Leadiant Biosciences Inc.,
Gaithersburg, MD 20878
Made in Switzerland
CYSTARAN
cysteamine hydrochloride solution |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Labeler - Leadiant Biosciences, Inc. (068301431) |